Cebranopadol: a Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist

Klaus Linz ¹, Thomas Christoph ¹, Thomas M. Tzschentke, Thomas Koch, Klaus Schiene, Michael Gautrois, Wolfgang Schröder, Babette Y. Kögel, Horst Beier, Werner Englberger, Stefan Schunk, Jean De Vry, Ulrich Jahnel, and Stefanie Frosch

Departments of Preclinical Drug Safety (K.L.), Global Preclinical Drug Development (S.F.), Global Preclinical Research and Development (U.J.), Pain Pharmacology (T.C., T.M.T., B.Y.K., K.S., J.D.V.), Molecular Pharmacology (T.K., W.E.), Translational Science (W.S.), Pharmacokinetics (M.G., H.B.), and Medicinal Chemistry (S.S.), Grünenthal GmbH, Aachen, Germany
Running title: Cebranopadol: a potent NOP/opioid receptor agonist analgesic

Corresponding author:

Dr Klaus Linz,
Grüenthal GmbH,
Department of Preclinical Drug Safety,
Zieglerstrasse 6,
52078 Aachen,
Germany
Tel: +49 (0)241-569-2975
Fax: +49 (0)241-569-2646
E-mail: Klaus.Linz@grunenthal.com

Number of text pages: 47 (incl. title page, this page, references and figure legends)

Number of tables: 3

Number of figures: 10

Number of references: 57 (maximum 60)

Number of words in the Abstract: 250 (maximum 250)

Number of words in the Introduction: 745 (maximum 750)

Number of words in the Discussion: 1415 (maximum 1500)

Abbreviations:

[^3]H]DAMGO, (D-Ala^2,N-Me-Phe^4, glycinol^5)-enkephalin; 5-HT, serotonin; ANOVA, analysis of variance; BL, baseline; CCI, chronic constriction injury; CERB, Centre de Recherches Biologiques; CFA, complete Freund’s adjuvant; CHO-K1, Chinese
hamster ovary K1 cells; CI, confidence interval; CI-977, enandoline ((5R)-(5 alpha,7 alpha,8 beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro [4,5]dec-8-yl-4-benzofuran-acetamide monohydrochloride); CNS, central nervous system; DMSO, dimethyl sulfoxide; DOP, delta opioid peptide; $E_{\text{max}}$, maximum possible effect for the agonist; EVF, electronic von Frey; GTP$_{\gamma}$S, guanosine-5'-[\gamma-thio]triphosphate; HCl, hydrochloride; HEK293, human embryonic kidney cell line 293; IC$_{50}$, half maximal inhibitory concentration; i.v., intravenous; J-113397, 1-[(3$R$,4$R$)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2$H$-benzimidazol-2-one; $K_i$, dissociation constant for inhibitor binding; KOP, kappa opioid peptide; MgCl$_2$, magnesium chloride; MOP, mu opioid peptide; MPE, maximum possible effect; MRMT-1, rat mammary gland carcinoma; NOP, nociceptin/orphanin FQ peptide; Ro64-6198, 8-[(1$S$,3$aS$)-2,3,3$a$,4,5,6-hexahydro-1$H$-phenalen-1-yl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one; SNC 80, (+)-4-[(a$R$)-a-((2$S$,5$R$)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide; SNL, spinal nerve ligation; STZ, streptozotocin; U69,593, (+)-(5$\alpha$,7$\alpha$,8$\beta$)-N-Methyl-$N$-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide.

**Recommended section assignment:** Neuropharmacology
ABSTRACT

Cebranopadol (trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine) is a novel analgesic nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonist (Kᵢ [nM]/EC₅₀ [nM]/relative efficacy [%]: human NOP receptor 0.9/13.0/89; human mu opioid peptide [MOP] receptor 0.7/1.2/104; human kappa opioid peptide receptor 2.6/17/67; human delta opioid peptide receptor 18/110/105). Cebranopadol exhibits highly potent and efficacious antinociceptive and antihypersensitive effects in several rat models of acute and chronic pain (tail-flick, rheumatoid arthritis, bone cancer, spinal nerve ligation, diabetic neuropathy) with ED₅₀ values of 0.5–5.6 µg/kg after intravenous and 25.1 µg/kg after oral administration. In comparison to selective MOP receptor agonists, cebranopadol was more potent in models of chronic neuropathic than acute nociceptive pain. Cebranopadol’s duration of action is long (up to 7 h after intravenous 12 µg/kg; > 9 h after oral 55 µg/kg in the rat tail-flick test). The antihypersensitive activity of cebranopadol in the spinal nerve ligation model was partially reversed by pretreatment with the selective NOP receptor antagonist J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one) or the opioid receptor antagonist naloxone, indicating that both NOP and opioid receptor agonism are involved in this activity. Development of analgesic tolerance in the chronic constriction injury model was clearly delayed compared with that from an equi-analgesic dose of morphine (complete tolerance on day 26 versus day 11, respectively). Unlike morphine, cebranopadol did not disrupt motor coordination and respiration at doses within and exceeding the analgesic dose range. Cebranopadol, by its combination of agonism at NOP and opioid receptors, affords highly potent and efficacious analgesia in various pain models with a favorable side-effect profile.
Introduction

Almost 20 years ago, a new member of the opioid receptor family and its endogenous agonist were described (Meunier et al., 1995; Reinscheid et al., 1995). Due to its partial homology to the opioid receptors (mu opioid peptide [MOP] receptor; delta opioid peptide [DOP] receptor; kappa opioid peptide [KOP] receptor), and its insensitivity to the prototypical opioid agonist and antagonist ligands, morphine and naloxone, this receptor was initially termed opioid-receptor-like receptor, ORL1. Subsequently, it was renamed the nociceptin/orphanin FQ peptide (NOP) receptor after its endogenous ligand, nociceptin, and it is now considered to be a non-opioid member of the opioid receptor family (Cox et al., 2009). At a cellular level, the actions of the NOP receptor are broadly similar to those of the opioid receptors (Chiou et al., 2007; Lambert, 2008). Although NOP receptors are clearly expressed at all levels of the pain pathways, it is thought that NOP and MOP receptors are not co-localized in the same neurons and may, thus, have independent actions in at least partly distinct neuronal networks (Monteillet-Agius et al., 1998).

The role of the NOP receptor in pain and analgesia has remained unclear for some time owing to inconsistent findings in early reports using nociceptin to activate the receptor. Being a peptide, nociceptin was administered locally into the central nervous system (CNS) where it produced both pronociceptive and antinociceptive effects when administered supraspinally (Meunier et al., 1995; Calo’ and Guerrini, 2013). Remarkably, when administered into the spinal cord of rodents and non-human primates, nociceptin consistently produced antinociceptive effects (Ko et al., 2009; Sukhtankar and Ko, 2013). Subsequent studies of systemic administration of non-peptide NOP receptor agonists revealed that such compounds were effective analgesics in animal pain models. Although evidence for antinociceptive and antihyperalgesic effects in rodents is limited and inconsistent (Jenck et al., 2000;
Reiss et al., 2008), Ko et al. (2009) demonstrated impressive antinociceptive and antiallodynic potency and efficacy using the NOP receptor agonist Ro64-6198 in Rhesus monkeys. Potency and efficacy were comparable to those of alfentanil, but with a complete absence of alfentanil-associated side effects such as itching/scratching and respiratory depression, and no evidence of reinforcing effects (Ko et al., 2009; Podlesnik et al., 2011).

Currently, strong MOP receptor agonists are the most effective drugs for the treatment of moderate to severe acute and chronic pain. However, while these drugs provide potent analgesia, they also carry the risk of severe side effects such as respiratory depression, nausea, vomiting, and constipation, and their use may lead to physical dependence and tolerance (Zöllner and Stein, 2007). In addition, opioids are considered to have limited efficacy in treating chronic nociceptive and neuropathic pain owing to a reduction in the already low therapeutic index (Labianca et al., 2012; Rosenblum et al., 2008). For these reasons, there is an unmet medical need for potent and well-tolerated analgesics for the treatment of moderate to severe chronic nociceptive and neuropathic pain.

As NOP and opioid receptor agonists modulate pain and nociception via distinct yet related targets, combining both mechanisms may constitute an interesting and novel approach for the development of innovative analgesics. Notably, a supra-additive interaction between intrathecal morphine and intrathecal nociceptin has been described in rodents (Courteix et al., 2004), as well as an enhancement of the antinociceptive effect of systemic morphine by systemic administration of Ro64-6198 (Reiss et al., 2008). Furthermore, a synergistic effect of concurrent NOP and MOP receptor activation without significant side effects has been demonstrated in non-human primates after systemic administration (Cremeans et al., 2012). At the same time, activation of NOP receptors has been proposed to counteract supraspinal...
opioid activity; in animal studies, NOP receptor agonists do not generate typical opioid-like side effects, and may even ameliorate opioid-related side effects when administered concurrently with an opioid agonist (Ko et al., 2009; Rutten et al., 2010; Toll, 2013). Thus, a combination of NOP and opioid receptor activation may be particularly suited to provide potent analgesia with reduced opioid-like side effects.

In order to explore the potential benefits of NOP and opioid receptor co-activation, novel compounds acting as agonists on both NOP and opioid receptors have been designed (Molinari et al., 2013; Zaveri et al., 2013). This paper describes the preclinical pharmacology of cebranopadol (Fig. 1), a potent NOP and opioid receptor agonist derived from a novel chemical series of spiro[cyclohexane-dihydropyrano[3,4-b]indol]-amines (Schunk et al., 2014, ACS Medicinal Chemistry Letters, submitted), that was developed by Grünenthal (Aachen, Germany) and is currently in clinical development for the treatment of severe chronic pain.
Materials and Methods

Animals

In Vitro Studies. Membrane suspensions used for rat brain receptor binding studies were obtained from male Sprague-Dawley specific-pathogen-free rats (average weight 200 g) (Charles River Laboratories, Sulzfeld, Germany).

In Vivo Studies. Behavioral studies in pain models and pharmacokinetic evaluations were conducted in Sprague-Dawley rats (weight range 134−423 g; tail-flick model: Iffa Credo, Brussels, Belgium; bone cancer model: Harlan Laboratories, Indianapolis, IN, USA; all other pain models and pharmacokinetics: Janvier Labs, Le Genest Saint Isle, France); male rats were used for most of the experiments, except for the tail-flick and bone cancer models, for which female Sprague-Dawley rats were used. Studies in side-effect models were conducted in male Wistar rats (weight range 150−375 g; Dépré, Saint Doulchard, France). Rats were housed under standard conditions (room temperature 20−24°C, 12 h light−dark cycle, relative air humidity 35−70%, 10−15 air changes per hour, air movement < 0.2 m/sec) with food and water available ad libitum in the home cage. Animals were used only once in all in vivo models, except for models of mononeuropathy, for which they were tested repeatedly with a wash-out period of at least 1 week between tests. Apart from the exceptions mentioned below, animal testing was performed in accordance with the recommendations and policies of the International Association for the Study of Pain (Zimmermann, 1983) and the German Animal Welfare Law. All study protocols were approved by the local government committee for animal research, which is advised by an independent Ethics Committee. Animals were assigned randomly to treatment groups. Different doses and vehicles were tested in a randomized fashion. Although the operators performing the behavioral tests were not formally ‘blinded’ with respect
to the treatment, they were not aware of the study hypothesis or the nature of differences between drugs.

Experiments in the bone cancer pain model were conducted in accordance with the International Association for the Study of Pain guidelines and were approved by the Algos Therapeutics Institutional Animal Care and Use Committee (Algos Therapeutics Inc., Saint Paul, MN, USA). Experiments in the side-effect models were conducted in accordance with French Animal Welfare Law and were approved by the Centre de Recherches Biologiques (CERB) Internal Ethics Committee (Baugy, France). For the bone cancer pain and side-effect models, animals were assigned randomly to treatment groups. Different doses and vehicles were tested in a randomized and blinded fashion.

Group sizes for the behavioral studies and pharmacological evaluations were as follows: $n = 10$ for the tail-flick, streptozotocin (STZ)-induced diabetic polyneuropathy, spinal nerve ligation (SNL), and rota rod models; $n = 8$ for the complete Freund’s adjuvant (CFA)-induced arthritis and whole-body plethysmography models; $n = 8–14$ for the bone cancer pain model; $n = 13–15$ for the chronic constriction injury (CCI) model; and $n = 4$ for the pharmacokinetic studies.

**In Vitro Studies**

**Receptor Binding Assay.** Human MOP, DOP, KOP, and NOP receptor binding assays were run in microtiter plates (Costar® 3632; Corning Life Sciences, Tewksbury, MA, USA) with wheat germ agglutinin-coated scintillation proximity assay beads (GE Healthcare, Chalfont St Giles, UK). Cell membrane preparations of CHO-K1 cells transfected with the human MOP receptor (Art.-No. RBHOMM, lot-No. #307-065-A) or the human DOP receptor (Art.-No. RBHODM, lot-No. #423-553-B), and HEK293 cells transfected with the human NOP receptor (Art.-No. RBHORLM, Lot-
No. #1956) or the human KOP receptor (Art.-No. 6110558, Lot-No. #295-769-A) were purchased from PerkinElmer Life Sciences Inc. (Boston, MA, USA). [N-Allyl-2,3-3H]naloxone and [Tyrosyl-3,5-3H]deltorphin II (both purchased from PerkinElmer Life Sciences Inc., Boston, MA, USA), [3H]Ci-977 and [Leucyl-3H]nociceptin (both purchased from GE Healthcare UK Ltd., Little Chalfont, UK) were used as ligands for the MOP, DOP, KOP, and NOP receptor binding studies, respectively. The K_D values of the radioligands used for the calculation of K_i values are provided as supplemental information (Supplemental Table 1). The assay buffer used for the MOP, DOP, and KOP receptor binding studies was 50 mM Tris-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co., St Louis, MO, USA). For the NOP receptor binding studies, the assay buffer used was 50 mM HEPES, 10 mM MgCl_2, 1 mM EDTA (pH 7.4). The final assay volume of 250 µl per well included 1 nM [3H]naloxone, 1 nM [3H]deltorphin II, 1 nM [3H]Ci-977, or 0.5 nM [3H]nociceptin as a ligand and cebranopadol in dilution series. Cebranopadol was diluted with 25% dimethyl sulfoxide (DMSO) in water to yield a final 0.5% DMSO concentration, which also served as a respective vehicle control. Assays were started by the addition of beads (1 mg beads/well), which had been preloaded for 15 min at room temperature with 23.4 µg human MOP membranes, 12.5 µg human DOP membrane, 45 µg human KOP membranes, or 25.4 µg human NOP membranes per 250 µl of final assay volume. After short mixing, the assays were run for 90 min at room temperature. The microtiter plates were then centrifuged for 20 min at 500 rpm, and the signal rate was measured by means of a 1450 MicroBeta® Trilux (PerkinElmer/Wallac GmbH, Freiburg, Germany). Half maximal inhibitory concentration (IC_50) values reflecting 50% displacement of [3H]naloxone-, [3H]deltorphin II-, [3H]Ci-977-, or [3H]nociceptin-specific receptor binding were...
calculated by nonlinear regression analysis. Individual experiments were run in duplicate and were repeated three times in independent experiments.

Rat MOP, KOP, and NOP receptor binding assays were run using membrane suspensions from rat brain without the cerebellum for MOP receptors; without the pons, medulla oblongata, and cerebellum for NOP receptors, and without the pons, medulla oblongata, cerebellum, and cortex for KOP receptors and the following tritium-labeled radioligands: \([^{3}H]\text{DAMGO}\) (purchased from PerkinElmer Life Sciences Inc., Boston, MA, USA) in the MOP receptor assay, \([^{3}H]\text{nociceptin}\) in the NOP receptor assay, and \([^{3}H]\text{Ci-977}\) in the KOP receptor assay. The assay buffer used for the binding studies was 50 mM Tris-HCl (pH 7.4) supplemented with 0.05% sodium azide (Sigma-Aldrich Co., St Louis, MO, USA). The final assay volume of 250 µl per well included 2 nM \([^{3}H]\text{DAMGO}\), 1 nM \([^{3}H]\text{nociceptin}\), or 1 nM \([^{3}H]\text{Ci-977}\) as a ligand in the MOP, NOP, or KOP receptor assays, respectively, and cebranopadol in dilution series. Cebranopadol was diluted with 25% DMSO in water to yield a final 0.5% DMSO concentration, which also served as a respective vehicle control. The assays were started by the addition of the membrane suspensions and, after short mixing, the assays were run for 90 min at room temperature. All incubations were run in triplicate and terminated by rapid filtration under mild vacuum (Brandel cell harvester type M-24 R; Brandel Inc., Gaithersburg, MD, USA) and two washes of 5 ml buffer using FP-100 Whatman GF/B filter mats (Whatman Schleicher and Schuell, Keene, NH, USA). The radioactivity of the samples was counted after a stabilization and extraction period of at least 15 h by use of the scintillation fluid Ready Protein (Beckman Coulter GmbH, Krefeld, Germany); the complete competition curves for cebranopadol were recorded.

**Off-Target Pharmacology Profile.** To obtain a selectivity profile for cebranopadol, its interaction with more than 100 different binding sites (including
voltage-gated ion channels, neurotransmitter transporters, ionotropic and metabolic receptors, and enzymes) was tested by BioPrint® (Cerep SA, Poitiers, France) according to Cerep standard assay protocols (Cerep, 2014).

**Agonist-stimulated [^{35}S] Guanosine-5'-[\gamma-thio]triphosphate Binding.** The \[^{35}S\]guanosine-5'-[\gamma-thio]triphosphate (GTP\(\gamma\)S) assay was carried out as a homogeneous scintillation proximity assay as described previously (Gillen et al., 2000), with the following modifications. The \[^{35}S\]GTP\(\gamma\)S assay was run in microtiter plates (Costar 3632), in which each well contained 1.5 mg of wheat germ agglutinin-coated scintillation proximity assay beads in a final volume of 200 µl. To test the agonistic activity of cebranopadol on human recombinant MOP, DOP, or NOP receptor-expressing cell membranes from CHO-K1 cells, or KOP receptor-expressing cell membranes from HEK293 cells, 10 µg of membrane proteins per assay were incubated with 0.4 nM \[^{35}S\]GTP\(\gamma\)S (GE Healthcare, Cardiff, UK) and different concentrations of agonists in buffer containing 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl\(\text{2}\), 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN\(\text{3}\), and 10 µM guanosine diphosphate for 45 min at 25°C. The bound radioactivity was determined as previously described (Tzschentke et al., 2007).

**In Vivo Studies**

Behavioral studies in pain models and pharmacokinetic evaluations were conducted in the laboratories of Grünenthal (Grünenthal GmbH, Aachen, Germany) apart from the studies in the bone cancer model and the side-effect models, which were conducted at Algos Therapeutics Inc. (Saint Paul, MN, USA) and CERB, respectively, under the sponsorship of Grünenthal GmbH.

**Tail-flick Model of Acute Nociceptive Pain.** The tail-flick test was carried out in rats using a modification of the method described by D’Amour and Smith (1941).
The tail-flick latency in seconds, the time to withdraw the tail from a radiant heat source (bulb 8V/50W), was measured using a semi-automated device (tail-flick analgesiometer Typ 50/08/1.bc; Labtec, Dr Hess, Aachen, Germany). The heat source was adjusted to produce a baseline (BL) tail-flick latency of 3−5 s, a cut-off time of 12 s was used to prevent tissue damage in animals showing no response. The maximum possible antinociceptive effect was defined as the lack of a tail-flick reaction up to the cut-off time of 12 s. The maximum possible effect (% maximum possible effect [MPE]) was calculated according to the formula:

\[
\frac{(T1 - T0)}{(T2 - T0)} \times 100
\]

where T0 and T1 were latencies before and after intravenous or oral drug administration, respectively, and T2 was the cut-off time.

**CFA-induced Arthritis Model of Chronic Inflammatory Pain.** Rats were anesthetized using 3% isoflurane in oxygen and the left knee was injected according to Butler and coworkers (Butler et al., 1992) with 150 µl of CFA, containing 2 mg/ml of inactivated and dried *Mycobacterium tuberculosis*. The right hind limb joint remained untreated. Animals were assessed for changes in weight bearing 5 days after intra-articular injection using a rat incapacitance tester (Somedic Sales AB, Hörby, Sweden). Rats were placed in the angled Plexiglas chamber of the incapacitance tester with their hind paws on separate sensors, and the percentage body weight distribution was calculated over a 30 s period. The percentage of contralateral weight bearing was calculated, with 100% values resulting from equal weight distribution across both hind limbs. Data are expressed as % MPE according to the formula:

\[
\% \text{ MPE} = \frac{(TP_S - TP_0)}{(0 - TP_0)} \times 100
\]

where TP0 = reduction of threat power [%] before substance application, TP S = reduction of threat power [%] after substance application, and TP [%] = 100 –
[(WB_{\text{ipsi}} \times 100) / ((WB_{\text{ipsi}} - WB_{\text{contra}}) / 2)] \quad (WB_{\text{ipsi}} = \text{weight bearing of the ipsilateral paw treated with intra-articular CFA-injection}; WB_{\text{contra}} = \text{weight bearing of the contralateral untreated paw}).

**Bone Cancer Pain Model.** A rat model of bone cancer pain (Medhurst et al., 2002) was used to induce mechanical hypersensitivity. Rats were anesthetized with 2.5–5.0% isoflurane in oxygen. A small incision was made near the proximal end of the tibia and approximately 1000 mammary gland carcinoma (MRMT-1) cells were injected into the intramedullary space of the tibia in a 3 μl volume using a Hamilton syringe. The hole in the bone was sealed with Lukens™ bone wax (Surgical Specialties Corp., Reading, PA, USA) and the skin was closed with wound clips. Experiments were conducted 16–18 days after surgery. BL and post-treatment values for mechanical sensitivity were evaluated using an electronic von Frey (EVF) apparatus (IITC Life Science, Woodland Hills, CA, USA). Reduced maximum force to withdrawal on the ipsilateral relative to the contralateral side is interpreted as a measure of increased mechanical sensitivity. Animals were placed on a wire mesh platform and allowed to acclimatize to their surroundings for a minimum of 30 min before testing. The mean of the three EVF thresholds was determined for each hind paw per time point. Consecutive testing alternated between ipsilateral and contralateral paws within the testing groups. The mean ± S.E.M. across animals was determined for each treatment group. Animals were tested 60 min prior to administration of the test compound or vehicle (BL) and 30, 60, and 180 min after administration of the test compound or vehicle. Withdrawal thresholds of the injured ipsilateral paws are expressed as:

\[
\% \text{ MPE} = (\text{Test}_{\text{individual}} - \text{BL}_{\text{individual}}) \times 100 / (\text{BL}_{\text{mean contra}} - \text{BL}_{\text{mean ipsi}}).
\]

Withdrawal thresholds of the contralateral paws are expressed as \( \% \text{ MPE} = (\text{Test}_{\text{individual}} - \text{BL}_{\text{individual}}) \times 100 / (\text{BL}_{\text{mean contra}} - \text{BL}_{\text{mean ipsi}}) \times (\text{BL}_{\text{mean contra}} / \text{BL}_{\text{mean ipsi}}) \).
BLmeanipsi). A cut off was set at 100% MPE: values above 100% were considered as 100%. The effect of each compound and vehicle was calculated at each post-administration time point as intra-individual % MPE.

**STZ-induced Diabetic Polyneuropathy Model.** Rats were injected intraperitoneally with 75 mg/kg STZ (Sigma-Aldrich Chemie GmbH, Munich, Germany) dissolved in citrate solution (citric acid 0.1 M and Na₂HPO₄ x 2H₂O 0.2 M, with final volume to volume of 53.7/46.3 and final pH of 4.6). Diabetes was confirmed 1 week later by measurement of tail vein blood glucose level by Haemo-Glukotest 20R-800R® (Boehringer Mannheim GmbH, Mannheim, Germany) and a reflectance colorimeter (Hestia Pharma GmbH, Mannheim, Germany). Rats with a final blood glucose level of at least 17 mM were considered diabetic and were included in the study. Control animals were treated with citrate solution. Rats were submitted to the paw pressure test previously described by Randall and Selitto (1957). Mechanical nociceptive thresholds were assessed using an Algesiometer (Ugo Basile Srl, Comerio, Italy) by measuring withdrawal thresholds to an increasing pressure stimulus onto the dorsal surface of the right hindpaw. The maximum pressure was set at 500 g and the endpoints were paw withdrawal, vocalization, or overt struggling. Tests took place during week 3 after the induction of diabetes. The mechanical nociceptive threshold was measured 30 min before injection of the test compound or vehicle, and 15, 30, 45, and 60 min after administration of the test compound or vehicle in both diabetic and control animals. Antihyperalgesic efficacy was shown as withdrawal thresholds of the diabetic animals, expressed as:

\[
\% \text{ MPE} = \frac{\text{Test}_{\text{individual}} - \text{BL}_{\text{individual}}}{\text{BL}_{\text{mean Citrate}} - \text{BL}_{\text{mean STZ}}} \times 100
\]

Antinociceptive efficacy was shown as withdrawal thresholds of the non-diabetic animals, expressed as \(\% \text{ MPE} = \frac{(\text{Test}_{\text{individual}} - \text{BL}_{\text{individual}}) \times 100}{(\text{BL}_{\text{mean Citrate}} - \text{BL}_{\text{mean STZ}}) \times (\text{BL}_{\text{mean Citrate}} / \text{BL}_{\text{mean STZ}})}\). A cut-off was set at 100% MPE: values
above 100% were considered as 100%. The effect of each compound and the pooled vehicle groups were calculated for each testing time point as intra-individual % MPE.

**SNL Model.** Under pentobarbital anesthesia (Narcoren® 60 m/kg i.p.; Merial GmbH, Hallbergmoos, Germany), the L5/L6 spinal nerves were tightly ligated according to the method by Kim and Chung (Kim and Chung, 1992). After surgery, the animals were allowed to recover for 1 week. The threshold for tactile allodynia was measured with an EVF anesthesiometer (Somedic, Malmö, Sweden). Animals were tested 30 min prior to administration of the test compound or vehicle (BL) and 30, 60, and 180 min after administration of the test compound or vehicle. The median withdrawal threshold for each animal at a given time was calculated from five individual stimulations with the EVF filament. Withdrawal thresholds of the ipsilateral paw are expressed as % MPE by comparing the BL threshold of the L5/L6-ligated animals (= 0% MPE) and the control threshold of the sham animals (= 100% MPE). A cut off was set at 100% MPE: values above 100% were considered as 100%. The effect of each test compound and vehicle was calculated at each post-administration time point as intra-individual % MPE value. In the antagonism experiments, J-113397 1.0, 2.15, and 4.64 mg/kg i.p. (Grünenthal GmbH, Aachen, Germany), naloxone 0.1, 0.3, and 1 mg/kg i.p., or vehicle were administered 5 min before cebranopadol 1.7 µg/kg intravenous (i.v.), morphine 8.9 mg/kg i.v., or vehicle. The animals were tested 30 min before and 30, 60, and 180 min after drug administration.

**Tolerance Development in the CCI Model.** Under pentobarbital anesthesia (Narcoren® 60 mg/kg i.p.), unilateral multiple ligations were performed at the right common sciatic nerve according to the method by Bennett and Xie (Bennett and Xie, 1988). After surgery, the animals were allowed to recover for 1 week. The animals develop cold allodynia, which is stable for at least 6 weeks. Cold allodynia is tested on a metal plate cooled by a water bath to a constant temperature of 4°C. The
animals were placed on the cold plate for 2 min and the number of brisk withdrawal reactions was counted. The animals were observed on the cold plate for periods of 2 min at 30 min before and 30 min after administration of test compound or vehicle and the number of brisk withdrawal reactions was counted. % MPE of each time point was calculated according to the formula: \[ \frac{(T0-T1)}{T0} \times 100 \], where T0 and T1 were numbers of paw withdrawal reactions before and after drug administration, respectively. The intraperitoneal route of administration was chosen to avoid tissue damage of the tail veins due to daily dosing. Antiallodynia was measured following administration of cebranopadol on days 1, 3, 5, 8, 12, 15, 17, 19, 22, 24, 26, and 29, and following administration of morphine on days 1 and 11.

**Rota Rod Test.** To investigate potential effects on motor coordination, an adapted rota rod test was performed (Dunham and Miya, 1957; Cartmell et al., 1991) using a constant speed device (Rota-Rod for rats, LE8500, Panlab SLU, Barcelona, Spain). The time that the animals remained on the rod was measured before and after administration of the test compound. One day prior to the experiment, the animals were trained at a speed of 5 revolutions per minute for a maximum of 5 attempts of 1 min. On the day of the test, the animals were placed on the rod rotating at a speed of 15 revolutions per minute. Any animals that fell consistently within 1 min over 5 consecutive attempts were not included in the study. In order to determine baseline values, selected animals were placed on the rod rotating at a speed of 15 revolutions per minute 3 times in succession. The duration of the longest attempt was considered for analysis (cut-off time: 2 min). This measurement was repeated 5 min after administration of cebranopadol or its vehicle, or 30 min after administration of morphine or its vehicle.

**Whole-body Plethysmography.** Respiration was measured by whole-body plethysmography (Chand et al., 1993). The day prior to assessment of respiratory
parameters, a polyethylene catheter was inserted into the femoral vein (for intravenous administration) or subcutaneously in the back of the rat in the lumbar area (for subcutaneous administration) under sodium pentobarbital (45 mg/kg, i.p.) anaesthesia. On the study day, the animals were placed in a whole-body plethysmograph (Emka Technologies SA, Paris, France). The administration catheter was connected to a sealed rotating connection device fitted at the top of the plethysmograph leaving the animal free to move. At least 15 min after the start of measurements and stabilization of the respiration signal, the animals were dosed. Measurements continued for 4 h after dosing. Respiration was measured for a period of 10 s at regular 1-min intervals using the Dataquest ART™ acquisition and analysis system version 4.1 (Data Sciences International, St Paul, MN, USA) at a sampling frequency of 500 Hz. Each respiratory cycle was analyzed using RS/1™ software version 6.0.1 (Brooks Automation Inc., Chelmsford, MA, USA) in order to determine the mean value of the following parameters: respiratory rate (cycles/minute), tidal volume (ml), peak inspiratory flow (ml/second), peak expiratory flow (ml/second), inspiration time (ms), and expiration time (ms). From these parameters, minute volume (ml/minute) was calculated as tidal volume * respiratory rate and airway resistance index (Enhanced Pause; PenH units) was calculated from expiration time and peak inspiratory and expiratory flows according to Chong et al. (1998). Each parameter was analyzed immediately before dosing and 10, 15, 30, 60, 90, 120, 180, and 240 min after dosing.

**Pharmacokinetic Characterization.** The pharmacokinetic properties of cebranopadol in rats were investigated after a single intravenous dose of 160 µg/kg of cebranopadol. The intravenous dose was administered as a bolus in a volume of 2 ml/kg with a catheter in the vena femoralis. Blood samples (200 µl/sample) were withdrawn via an implanted arterial catheter (arteria carotis) by an automated blood
sampling system (Culex®; Bioanalytical Systems Inc., West Lafayette, IN, USA) at the following sampling times: 0 (predose), 5, 15, 30, 60, 180, 360, 720, and 1440 min after administration. Blood samples were centrifuged and plasma was separated. Plasma concentrations of cebranopadol were determined using a validated liquid chromatography−tandem mass spectrometry method. The lower limit of quantification for cebranopadol in this method was 0.05 ng/ml using a sample volume of 50 µl plasma.

**Data Analysis**

**In Vitro Studies.** IC₅₀ values were calculated using the Figure P computer software version 6.0c (Biosoft, Cambridge, UK), and dissociation constant for inhibitor binding (Kᵢ) values were obtained using the Cheng–Prusoff equation (Cheng and Prusoff., 1973). Equilibrium dissociation constant values were calculated using the Ligand computer software, version 4 (Biosoft, Cambridge, UK).

**Tail-flick, Bone Cancer Pain, SNL, CCI, and STZ Diabetic Hyperalgesia Models.** Data were analyzed by means of one- or two-factor analysis of variance (ANOVA), with or without repeated measures, depending on the experimental design. Significance of treatment, time, or treatment by time interaction effects was analyzed by means of Wilks’ Lambda. In case of a significant treatment effect, pairwise comparisons were performed by post hoc analysis using the Bonferroni test. Results were considered statistically significant if p < 0.05. ED₂₅, ED₅₀, or ED₇₅ values and 95% confidence intervals (CIs) were determined at the time of the peak effect by semi-logarithmic regression analysis or according to Litchfield and Wilcoxon (Litchfield and Wilcoxon, 1949) based on % MPE data.

**CFA-induced Arthritis Model.** Data were analyzed by means of two-factor repeated-measures ANOVA. Significance of treatment, time, or treatment by time
interaction effects was analyzed by means of Wilks’ Lambda. In case of a significant
treatment effect, pair-wise comparisons were performed at the different time points
using Fisher’s least significant difference test followed by a post hoc Dunnett test.
Results were considered statistically significant if \( p < 0.05 \).

**Rota Rod Test.** Results are expressed as median with 25th and 75th
percentiles. Effects induced by cebranopadol or morphine were compared with those
of their respective vehicles using the Kruskal–Wallis test followed by a non-
parametric Mann–Whitney U test (unilateral comparison). Statistical tests were
processed using RS/1\(^{TM}\) software version 6.0.1. Results were considered statistically
significant if \( p < 0.05 \).

**Whole-body Plethysmography.** Results were expressed as mean ± S.E.M.
Homogeneity between groups of baseline values for the parameters measured was
tested using ANOVA. The effects of cebranopadol, morphine, or their vehicles were
expressed as percentage of change from baseline values, with the exception of
airway resistance index that was expressed as variation (i.e. in PenH units) from
baseline values. Statistical analysis was conducted using repeated measures
ANOVA with Newman–Keuls post hoc test in case of significance using RS/1\(^{TM}\)
software version 6.0.1. Results were considered statistically significant if \( p < 0.05 \).

**Drugs and Chemicals**

The following drugs were used: cebranopadol hemi-citrate (Grünenthal GmbH,
Aachen, Germany), fentanyl citrate (CAS no.: 990-73-8; Synopharm GmbH,
Barsbüttel, Germany), J-113397 (CAS no.: 2177461-40-0; Grünenthal GmbH,
Aachen, Germany), morphine HCl (CAS no.: 52-26-6; Merck AG, Darmstadt,
Germany), morphine sulfate (CAS no.: 6211-15-0; Baxter, Cherry Hill, NJ, USA),
sodium pentobarbital (CAS no.: 57-33-0; Narcoren\(^{®}\)), naloxone HCl (CAS no.: 51481-
60-8; Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany), nociceptin (CAS no.: 170713-75-4; NeoMPS, Strasbourg, France), DAMGO (CAS no.: 78123-71-4; Bachem AG, Bubendorf, Switzerland), SNC 80 (CAS no.: 156727-74-1; Enzo Life Sciences GmbH, Lörrach, Germany), and U69,593 (CAS no.: 96744-75-1; Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany).

The following chemicals were used: cremophor EL, DMSO, 5% glucose (Sigma-Aldrich Co., St Louis, MO, USA; Sigma-Aldrich Chemie GmbH, Munich, Germany), saline (Baxter, Cherry Hill, NJ, USA; Baxter, Unterschleißheim, Germany). For the in vivo studies, cebranopadol hemi-citrate was dissolved in 10% DMSO/5% Cremophor EL/85% glucose solution (5%), except for tail-flick and whole body plethysmography models (5% DMSO in 95% glucose solution [5%]), and the CFA-induced arthritis model (5% DMSO, 5% Cremophor EL in 90% glucose solution [5%]). Administration volume was 10 ml/kg (tail-flick, rota rod, and whole body plethysmography models), 1 ml/kg (bone cancer pain model), or 5 ml/kg (all other in vivo models).

Morphine HCl, morphine sulfate and fentanyl citrate were dissolved in physiological saline solution. Administration volume was 10 ml/kg (tail-flick model), 2 ml/kg (rota rod and whole body plethysmography models), or 1 ml/kg (bone cancer pain model).

Unless otherwise indicated, the route of administration for cebranopadol, fentanyl, and morphine was intravenous. Cebranopadol was tested as the hemi-citrate salt in all in vitro and in vivo studies. Morphine was tested as the hydrochloride or sulfate salts and fentanyl as the citrate salt. All doses and ED$_{50}$ values indicated in the following sections refer to the respective free base. For simplicity, the salt forms have been omitted from the text.
Results

In Vitro Data

Cebranopadol binds with high affinity (subnanomolar to nanomolar range) to NOP and opioid receptors. Table 1 shows the $K_i$ of cebranopadol in human NOP, MOP, KOP, or DOP receptor binding assays. Cebranopadol showed the most pronounced binding affinities at human NOP and MOP receptors with subnanomolar inhibitory constants. In addition, cebranopadol showed an approximate 3–4-fold weaker binding affinity in a human KOP receptor binding assay, and an approximate 20–26-fold lower affinity in a human DOP receptor binding assay. A comparable binding profile was observed for rat NOP, MOP, and KOP receptors showing again high affinity binding to both NOP and MOP receptors, and a lower affinity to the KOP receptor. Binding data for the rat DOP receptor were not determined.

The agonistic activity of cebranopadol at the human NOP, MOP, KOP, or DOP receptors was tested in $[^{35}\text{S}]\text{GTP}^\gamma\text{S}$ binding assays with membranes from cells expressing the respective recombinant human receptors. Its potency ($EC_{50}$: concentration with half-maximum inducible $[^{35}\text{S}]\text{GTP}^\gamma\text{S}$ binding) and efficacy (percentage of maximum inducible $[^{35}\text{S}]\text{GTP}^\gamma\text{S}$ binding) were compared to the functional activity of the selective NOP receptor agonist nociceptin/orphanin FQ, the MOP receptor-selective enkephalin DAMGO, the KOP receptor-selective agonist U69,593, and the DOP receptor-selective agonist SNC 80. The latter are examples of fully efficacious agonists at the respective receptors in the $[^{35}\text{S}]\text{GTP}^\gamma\text{S}$ binding assay, and were used as comparators in order to set 100% relative efficacy with regard to the $[^{35}\text{S}]\text{GTP}^\gamma\text{S}$ binding rate at the respective receptors. Cebranopadol showed full agonistic efficacy at the human MOP and DOP receptors, almost full efficacy at the human NOP receptor, and partial efficacy at the human KOP receptor (Table 1).
Binding affinities to more than 100 neuronal and safety-relevant receptors, ion channels (including hERG), and enzymes tested in an extensive Cerep off-target profile were at least 100 to 1000 times lower than opioid receptor affinities and are considered biologically irrelevant. The only exception was the serotonin 5A (5-HT$_{5A}$) receptor for which a $K_i$ of 8.7 nM was determined. However, in a functional $[^{35}\text{S}]$GTP$_{\gamma}$S binding assay with membranes expressing human 5-HT$_{5A}$ receptor, cebranopadol did not show agonistic or significant antagonistic effects at concentrations up to 10.0 µM.

**Behavioral Tests**

$\text{ED}_{50}$ values (95% CI) from all pain models that are described in this section are summarized in Table 2. Morphine data are shown for comparison.

**Tail-flick Model.** In the tail-flick test, cebranopadol induced dose-dependent inhibition of heat nociception with $\text{ED}_{50}$ values (95% CI) of 5.6 (4.4–7.0) µg/kg i.v. and 25.1 (20.7–30.4) µg/kg p.o. The maximum attainable antinociceptive response was obtained at 17 µg/kg. i.v. or 80 µg/kg p.o. Peak effects were attained within 20 min after intravenous (Fig. 2) and 90 min after oral administration. The oral availability, estimated by calculating the ratio of intravenous versus oral $\text{ED}_{50}$ values, was 22.0% for cebranopadol.

Equi-effective dosages of the high-dose range (> 80% MPE) were chosen to characterize the duration of action of cebranopadol, fentanyl, and morphine. The duration of action after intravenous administration of 12 µg/kg cebranopadol lasted up to 7 h, where 10% MPE was measured. The effect of fentanyl and morphine declined within 30 and 180 min, respectively (Fig. 2). After oral administration of 55 µg/kg cebranopadol, long lasting and significant antinociception was demonstrated.
for at least 9 h (last test point measured), where 52% MPE was still attained (data not shown).

**CFA-induced Arthritis Model.** Intra-articular CFA injection induced chronic inflammation of the knee joint with a decrease in weight bearing of about 50–60% after 5 days. This time point coincided with the maximum difference in weight bearing, a state that lasted until 14 days after CFA-injection (data not shown). This reduction in weight bearing was reversed by cebranopadol in a dose-dependent manner, with a maximal effect of 63.0 ± 11.9% and 65.3 ± 6.0% after 30 and 60 min, respectively, at the dose of 8 µg/kg i.v. (Fig. 3). The calculated ED$_{50}$ (95% CI) was 5.5 (3.2–21.0) µg/kg i.v. 30 min after substance application (Table 2). The ED$_{50}$ was calculated in the dose range from 0.8 to 8.0 µg/kg i.v..

**Bone Cancer Pain Model.** Intravenous administration of cebranopadol 2.4, 8.0, and 24.0 µg/kg dose-dependently increased ipsilateral paw withdrawal thresholds 30, 60, and 180 min after dosing compared with EVF thresholds in vehicle-treated animals. Full efficacy was reached 60 min after administration and the resulting ED$_{50}$ value (95% CI) of 3.6 (1.6–7.0) µg/kg i.v. was calculated (Table 2). Contralateral paw withdrawals were increased compared with vehicle-treated animals. However, statistical significance was only reached at the 30- and 60-min time points for the highest dose tested (Fig. 4).

**STZ-induced Diabetic Polyneuropathy Model.** Cebranopadol was tested at 0.24, 0.8 and 2.4 µg/kg i.v. and showed dose-dependent and significant inhibition of mechanical hyperalgesia at all doses tested (Fig. 5). There was no effect on mechanical noxious thresholds in the tested doses because no significant effect was seen in control animals. The calculated ED$_{50}$ (95% CI) was 0.5 (0.2–0.8) µg/kg, 30 min after administration (Table 2).
SNL Model. Cebranopadol was tested at doses of 0.24, 0.8, 2.4 and 8.0 µg/kg i.v. and showed a dose-dependent inhibition of mechanical hypersensitivity (Fig. 3). The highest dose tested showed full efficacy with 93% MPE. Potency was quantified by an ED$_{50}$ value (95% CI) of 0.8 (0.5–1.1) µg/kg i.v. calculated from the peak effect versus control values at 30 min after administration (Table 2).

Antagonism in the SNL Model. For antagonism studies, cebranopadol 1.7 µg/kg i.v. and morphine 8.9 mg/kg i.v. were tested at doses that were known to be highly efficacious resulting in >70% MPE. Pretreatment with increasing doses (1.0, 2.15, and 4.64 mg/kg i.p.) of the selective NOP receptor antagonist J-113397 revealed dose-dependent antagonism of the antihypersensitive effect of cebranopadol (Fig. 6A), but no inhibition of the % MPE for morphine (Fig. 6B), suggesting selectivity of the NOP receptor antagonist. Pretreatment with naloxone 1.0 mg/kg i.p., but not with 0.3 mg/kg i.p., resulted in significant antagonism of the antihypersensitive effect of cebranopadol (Fig. 6C). Morphine was dose-dependently antagonized by naloxone 0.1–1.0 mg/kg i.p. (Fig. 6D); full antagonism was reached at naloxone 1.0 mg/kg.

Tolerance Development in the CCI Model. Cebranopadol 0.25 and 0.8 µg/kg were chosen as the medium and high doses for the tolerance experiment and were given by intraperitoneal injection once daily (Fig. 7A); allodynia was measured 30 min post-administration at multiple time points. Dose-dependent inhibition of cold allodynia was demonstrated. Complete tolerance to cebranopadol had developed by day 22 for the 0.25 µg/kg dose and by day 26 for the 0.8 µg/kg dose. Reference control experiments were performed with morphine dosed daily at 8.9 mg/kg i.p. The number of brisk withdrawal reactions (mean ± S.E.M.) was determined for the vehicle group and the morphine group on day 1 (vehicle 24.0 ± 1.11, morphine 11.0 ± 1.25, $p < 0.001$) and on day 11 (vehicle 23.0 ± 1.33, morphine 27.0 ± 1.69, $p = 0.095$)
suggesting that full tolerance to morphine had already developed by day 11. Fig. 7B shows a comparison in % MPE of the high dose cebranopadol with morphine and historical morphine data (10 mg/kg i.p.) generated under the same experimental conditions (Tzschentke et al., 2007).

**Opioid-type Side Effects**

The side-effect profile of cebranopadol was characterized by means of safety pharmacology studies in rats. These studies focused on the CNS and respiratory system as typical target organs for opioid-type side effects.

**Rota Rod Test.** In the rota rod test, cebranopadol was assessed at intravenous doses of 4, 8, and 16 µg/kg. Although these doses produced significant activity in pain models, they did not affect motor coordination (Fig. 8A). In contrast, morphine at intravenous doses of 2.7 and 8.9 mg/kg induced dose-dependent impairment of motor coordination. At these doses, the median time that the animals were able to remain on the rotating rod was significantly decreased from 120 s to 52 s and 3 s, respectively (Fig. 8B).

**Whole-body Plethysmography.** A whole-body plethysmography model was used to investigate potential effects of cebranopadol on respiratory function in conscious, freely moving rats. In this model, intravenous administration of vehicle or 4, 8, or 16 µg/kg cebranopadol induced a transient increase in respiratory rate and tidal volume (Fig. 9A). Statistical analysis revealed no significant difference between the treatments during the 4-h recording period. Consequently, cebranopadol did not significantly alter minute volume at any dose tested (Fig. 9C). Other respiratory parameters, including peak inspiratory and expiratory flows, inspiration and expiration times, and the calculated airway resistance index were also not significantly changed by administration of cebranopadol (Fig. 9C). The absence of any effect on respiratory
function was in clear contrast to the effects induced by subcutaneous morphine. Increasing doses of morphine 0.9, 8.9, and 26.6 mg/kg s.c. induced a dose-dependent decrease in tidal volume ($E_{\text{max}} = -37 \pm 8\%$ compared with baseline at 10 min after dosing), and a subsequent increase in respiratory frequency by up to $+42 \pm 11\%$ at 60 min after dosing (Fig. 9B). However, despite the increase in respiratory frequency, minute volume was dose-dependently reduced suggesting a respiratory depressive effect (Fig. 9D). This effect was statistically significant after 26.6 mg/kg s.c. ($E_{\text{max}} = -26 \pm 3\%$ compared with baseline at 10 min after dosing). Respiratory depression induced by morphine also became apparent from dose-dependent increases in inter-cycle variations in respiratory waveform and increases in the number and duration of pauses in respiratory rhythm (data not shown). In addition, morphine induced statistically significant decreases in peak inspiratory flow ($E_{\text{max}} = -42 \pm 3\%$ compared with baseline at 10 min after dosing) and expiration time ($E_{\text{max}} = -40 \pm 5\%$ compared with baseline at 60 min after dosing), as well as a significant increase in airway resistance index ($E_{\text{max}} = +0.39 \pm 0.04$ PenH units compared with baseline at 60 min after dosing) after 8.9 mg/kg s.c. and 26.6 mg/kg s.c. (Fig. 9D).

**Pharmacokinetic characterization**

The pharmacokinetic parameters of cebranopadol after intravenous bolus administration in rats are summarized in Table 3. Cebranopadol was rapidly absorbed and extensively distributed. Oral bioavailability in rats was 13–23%.
Discussion

Cebranopadol, a new chemical entity that is currently in clinical development for the treatment of severe chronic nociceptive and neuropathic pain, was derived from a novel chemical series of spiro[cyclohexane-dihydropyrano[3,4-b]indol]-amines (Schunk et al., 2014, ACS Medicinal Chemistry Letters, submitted). Compounds within this chemical series have been designed and synthetized as combined NOP and opioid receptor agonists. The aim was to develop new drugs that have the analgesic potential of strong opioids, but are associated with fewer opioid-type side effects, and are thus characterized by a markedly higher therapeutic index.

Cebranopadol binds with nanomolar affinity to the NOP receptor and to the three opioid receptor subtypes. Human receptor binding affinities decrease in the order NOP receptor ~ MOP receptor > KOP receptor > DOP receptor. A comparable relative binding profile was also shown for rat NOP, MOP, and KOP receptors. Cebranopadol has full agonistic activity at human MOP and DOP receptors, near-full activity at the human NOP receptor, and partial activity at the human KOP receptor. Affinities of cebranopadol to neuronal and safety-relevant targets were 100 to 1000 times lower than opioid receptor affinities. The only relatively high affinity determined for cebranopadol was for the 5-HT$_{5A}$ receptor, but this affinity was lower than the affinity to NOP and MOP receptors by approximately 8-fold. In addition, in a functional [$^{35}$S]GTP$_{\gamma}$S binding assay, cebranopadol exhibited neither significant agonistic or antagonistic effects at the human 5-HT$_{5A}$ receptor. Therefore, the affinity to this specific receptor is expected to be without biological relevance.

In rat models of acute, inflammatory, and bone cancer pain, as well as of chronic mono- and polyneuropathic pain, covering mechanical and thermal stimuli, cebranopadol was shown to be highly potent and efficacious. Cebranopadol is
characterized by a very long duration of action lasting up to 7 h after a single intravenous administration, which relates well to its long plasma half-life of about 4.5 h. Effective dose, characterized by $ED_{50}$ values, ranged from approximately 0.5 to 5.6 µg/kg after intravenous administration (see Table 2). Thus, cebranopadol was approximately 180 to 4800 times more potent in these models than the prototypic opioid receptor agonist morphine. Remarkably, the absolute potency of cebranopadol varied between different pain conditions. Potencies were comparable in a tail-flick model of acute nociceptive pain, in a CFA-induced arthritis model of inflammatory pain, and in conditions of hypersensitivity induced by bone cancer. In contrast, potency was about 10 times higher in chronic mononeuropathic pain induced by SNL and polyneuropathic pain caused by STZ-induced diabetes. This is in clear contrast to morphine, which has been shown to display similar potency in acute nociceptive, inflammatory, and bone cancer pain models, but to be less potent in chronic neuropathic pain (see Table 2 and Schiene et al., 2011; Bian et al., 1999; Christoph et al., 2007; Rashid et al., 2004). The loss of analgesic potency of opioids such as morphine in neuropathic pain states has been attributed to a decreased expression of presynaptic spinal (Kohno et al., 2005; Ossipov et al., 1995) and peripheral MOP receptors (Rashid et al., 2004). The increased analgesic potency of cebranopadol in models of neuropathic pain is in line with data on selective NOP receptor agonists, which have been shown to have a potent and efficacious antihypersensitive effect in rodent neuropathic pain models (Courteix et al., 2004; Ju et al., 2013; Linz et al., 2013; Obara et al., 2005; reviewed in Schroeder et al., 2014, British Journal of Pharmacology, submitted). Moreover, it was demonstrated that the antinociceptive potency of intrathecally administered nociceptin was greater in mice with diabetic polyneuropathy than in non-diabetic mice (Kamei et al., 1999). An increase in function of the NOP receptor system under these pathophysiological conditions has
been attributed to an upregulation of NOP receptors in dorsal root ganglia neurons (Briscini et al., 2002; Chen and Sommer, 2006). This might suggest a clinical benefit of compounds that are agonists at both NOP and opioid receptors over those that are agonists only at opioid receptors. Studies have shown that combining selective NOP and MOP receptor agonists led to co-activation of both receptor systems and to synergism of antiallodynic and antinociceptive effects in rodents (Courteix et al., 2004) and non-human primates (Cremeans et al., 2012), respectively. Based on the in vitro binding data, it is expected that agonism at both NOP and MOP receptors will contribute functionally to the analgesic activity of cebranopadol. Antagonism experiments were carried out to elucidate the contribution of NOP and opioid receptor agonism to antihypersensitivity in chronic neuropathic pain. The antihypersensitive activity of cebranopadol in the SNL model could be partially reversed by pretreatment with either the selective NOP receptor antagonist J-113397 (Ozaki et al., 2000) or the opioid receptor antagonist naloxone (Raynor et al., 1994). At the same antagonist doses, J-113397 did not affect the antihypersensitive effect of morphine, while naloxone produced full reversal of morphine activity. This observation points to a significant contribution of both NOP receptor and opioid receptor agonism to the antihypersensitive activity of systemic cebranopadol. More detailed analysis will be required to assess a potential intrinsic synergism between both mechanisms of action.

Besides the synergistic activity of NOP and opioid receptor agonism in analgesia, it was hypothesized that NOP receptor agonism at a supraspinal level may functionally counteract opioid-typical side effects (Ciccocioppo et al., 2000; Lutfy et al., 2001; Rutten et al., 2010; Shoblock et al., 2005). In particular, development of analgesic tolerance, which is a common limitation with chronic opioid treatment (Morgan and Christie, 2011), as well as rewarding effects were shown to be reduced
in rodents if a NOP receptor agonist was co-administered with a selective MOP receptor agonist. In the current study, tolerance to the antiallodynic effect of cebranopadol in the CCI model in the rat developed slowly. Complete tolerance against cebranopadol had developed after 22–26 days of repeated daily dosing, and was thus significantly delayed compared with morphine, for which complete tolerance occurred under the same experimental conditions after 11 days of repeated daily dosing. The latter data are in accordance with a previous report on the development of tolerance to morphine (Tzschentke et al., 2007). Whether the intrinsic NOP receptor agonism may also reduce or even largely prevent potential reinforcing effects or physical dependence of cebranopadol as postulated for bifunctional NOP and MOP receptor agonists (Toll, 2013) needs further investigation.

In order to characterize the side-effect profile of cebranopadol, safety pharmacology studies were carried out in rats. These focused on typical opioid-type side effects within the CNS and the respiratory system. Opioids such as morphine and oxycodone impair motor coordination within the antinociceptive dose range (Winter et al., 2003), as was confirmed in the present study. In the rota rod test in rats, morphine significantly impaired motor coordination starting at a dose that was about 2 times the ED₅₀ for antinociception in the rat tail-flick assay and 0.7 times the ED₅₀ for antihypersensitive activity in the rat SNL model (Fig. 10). In contrast, cebranopadol did not induce any effects in the rota rod test, even at the highest test dose of 16 µg/kg i.v., which was at least 3 times the ED₅₀ for antinociception in the tail-flick test and more than 30 times the ED₅₀ for antihyperalgesic activity in rats with STZ-induced neuropathic pain (Fig. 10). Comparable observations were made with respect to opioid-type respiratory depression. In a rat whole-body plethysmography model, even at the highest test dose of 16 µg/kg i.v., cebranopadol did not induce significant changes in respiratory parameters. By contrast, in the same model,
morphine induced dose-dependent alterations in respiratory parameters that resulted in profound respiratory depression at higher doses. Significant changes in tidal volume had already occurred at doses below the ED$_{50}$ for antinociception in the rat tail-flick assay and the ED$_{50}$ for antihypersensitive activity in neuropathic pain induced by SNL.

In conclusion, cebranopadol displays broad activity in various pain states, and is highly potent and efficacious in animal models of acute nociceptive, inflammatory, cancer and, especially, chronic neuropathic pain. In contrast to opioids such as morphine, cebranopadol displays higher analgesic potency in chronic pain, especially of neuropathic origin, than in acute nociceptive pain. In addition, even after doses higher than those required to induce analgesia, cebranopadol affects neither motor coordination nor respiratory function, and thus displays a better tolerability profile than opioids. As a result, there is a broader therapeutic window for cebranopadol than for morphine. As a NOP receptor and opioid receptor agonist, cebranopadol is a novel, first-in-class, potent analgesic under development for the treatment of severe chronic nociceptive and neuropathic pain.
Acknowledgments

The authors thank Wiltrud Charlier, Manuela Jansen, Nicole Kohl, Johanna Koroith, Antje Leipelt, Reinhard Lerch, Simone Schmitz, Elke Schumacher, Hans-Josef Weber, Simone Wigge, and Rene Woloszczak (all Grünenthal GmbH, Aachen, Germany) for their technical assistance in conducting of experiments, as well as Petra Günther, Silke Vickus (both Grünenthal GmbH, Aachen, Germany) for technical help with the manuscript. Writing support was provided by Dr Harriet Crofts of Oxford PharmaGenesis™ London, UK, and was funded by Grünenthal GmbH, Aachen, Germany.
Authorship Contributions

Participated in research design: Linz, Christoph, Schiene, Schröder, De Vry, Jahnel, and Frosch.

Conducted experiments: Linz, Christoph, Schiene, Gautrois, Schröder, Kögel, Beier, and Englberger.

Performed data analysis: Linz, Christoph, Gautrois, and Schröder.

Contributed new reagents or analytic tools: Schunk.

Wrote or contributed to the writing of the manuscript: Linz, Christoph, Tzschentke, Koch, Schiene, Gautrois, and Frosch.


Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. *Biochem Pharmacol* **22**: 3099-3108.


Sukhtankar D and Ko MC (2013) Pharmacological investigation of NOP-related ligands as analgesics without abuse liability, in Research and Development of Opioid-Related Ligands (Ko MC and Husbands SM eds) pp 393-416, American Chemical Society, Washington, DC.


Footnotes

This work was supported by Grünenthal GmbH, Aachen, Germany.

Address correspondence to: Dr Klaus Linz, Grünenthal GmbH, Preclinical Research and Development, Department of Preclinical Drug Safety, Zieglerstrasse 6, 52078 Aachen, Germany. E-mail: Klaus.Linz@grunenthal.com

¹ These authors contribute equally to this work.
Figure legends

Fig. 1. Chemical structure of trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine (cebranopadol).

Fig. 2. Duration of action of cebranopadol (12 µg/kg) compared to fentanyl (9.4 µg/kg) and morphine (1.9 mg/kg) after intravenous administration in the rat tail-flick test. Each point of the graph represents the mean ± S.E.M. of the maximum possible effect; n = 10 animals per group. *, p < 0.05 versus vehicle. Cebranopadol was tested as hemi-citrate salt, fentanyl was tested as citrate salt, and morphine was tested as hydrochloride salt. Doses refer to the respective free bases.

Fig. 3. Analgesic effect of cebranopadol on spinal nerve ligation-induced mononeuropathic pain (SNL) and complete Freund's adjuvant-induced chronic rheumatoid arthritic pain (CFA) 30 minutes after, and on tail flick-induced heat nociception (TF) 20 minutes after, intravenous administration. Data are expressed as mean percentage of maximum possible effect ± S.E.M. (n = 8–10). *, p < 0.05 versus vehicle.

Fig. 4. Effect of intravenous cebranopadol on mechanical sensitivity in the ipsilateral and contralateral paws in a rat model of bone cancer pain. Data are expressed as percentage of maximum possible effect (mean ± S.E.M.; n = 10–11) on mechanical withdrawal thresholds as measured with an electronic von Frey filament. *, p < 0.05 versus vehicle.

Fig. 5. Anti-hyperalgesic activity of cebranopadol in streptozotocin (STZ)-treated and control rats measured as % MPE (mean ± S.E.M.; n = 10) by means of mechanical
hyperalgesia in a model of STZ-induced diabetic polyneuropathy. *, \( p < 0.05 \) versus vehicle.

**Fig. 6** Effect of J-113397 1.0, 2.15, and 4.64 mg/kg i.p. on the antihypersensitive effect of cebranopadol 1.7 µg/kg i.v. (A) and morphine 8.9 mg/kg i.v. (B) in the spinal nerve ligation (SNL) model. Effect of naloxone 0.3 and 1.0 mg/kg, i.p. on the antihypersensitive effect of cebranopadol 1.7 µg/kg i.v. (C) and of naloxone 0.1, 0.3, and 1.0 mg/kg i.p. on the antihypersensitive effect of morphine 8.9 mg/kg i.v. (D) in the SNL model. Data are given as percentage of maximum possible effect (mean ± S.E.M.; \( n = 10 \)) measured with an electronic von Frey filament based on the measurement of ipsilateral withdrawal thresholds 30 min after administration of cebranopadol or morphine. *, \( p < 0.05 \) versus vehicle. NS, not significant.

**Fig. 7.** Antiallodynic effect of repeated daily i.p. administration of cebranopadol or vehicle as measured by number of paw lifts from a cold plate during 2 min (mean ± S.E.M.; \( n = 13-15 \)) (A) or % MPE (B) in the chronic constriction injury model. *, \( p < 0.05 \) versus vehicle. Morphine data (8.9 mg/kg i.p.; *reference control*) with repeated daily administration but measurement of alldynia only on day 1 and day 11 were tested as method control within the same experimental series as cebranopadol. Morphine data (8.9 mg/kg i.p.; *historical data*) with repeated testing are taken from Tzschtentke et al. (Tzschtentke et al., 2007) and were generated under the same experimental conditions.

**Fig. 8.** Dose-dependent effects of cebranopadol (A) and morphine (B) on motor coordination in rats. Results are expressed as time that the animals remained on the
rota rod (individual data, median values with interquartile range; \( n = 10 \) animals per group). *, \( p < 0.05 \) versus vehicle.

**Fig. 9.** Effects of cebranopadol (A and C) and morphine (B and D) on respiratory function in the whole-body plethysmography test in conscious rats. (A and B) Time course of effects on respiratory frequency (upper panels) and tidal volume (lower panels) (\( n = 8 \) animals per group). *, \( p < 0.05 \); **, \( p < 0.01 \) versus vehicle. (C and D) Maximum dose-dependent effects (\( E_{\text{max}} \)) on respiratory parameters expressed as changes from baseline. Time corresponding to the maximum effect is indicated for each parameter (\( n = 8 \) animals per group). *, \( p < 0.05 \); **, \( p < 0.01 \) versus vehicle.

**Fig. 10.** Comparison of potency and efficacy for cebranopadol (A) and morphine (B) in analgesic and side-effect models. ED\(_{25}\), ED\(_{50}\), and ED\(_{75}\) values are given for models of analgesia. No observed effect level (NOEL) and/or minimum effective dose values are given for side-effect models. Table 2 shows the ED\(_{50}\) values for the analgesic models. CFA, Complete Freund’s adjuvant-induced chronic rheumatoid arthritic pain; SNL, spinal nerve ligation-induced mononeuropathic pain; STZ, streptozotozin-induced diabetic polyneuropathy.
TABLE 1

Affinity and functional activity of cebranopadol at rat and human NOP, MOP, KOP, and DOP receptors.

Inhibition constants (Kᵢ) were determined in radioligand binding assays. Agonistic potencies (EC₅₀) and efficacies relative to selective and fully efficacious agonists at the respective receptors were tested in [³⁵S]GTPγS binding assays.

<table>
<thead>
<tr>
<th>Target</th>
<th>Rat Receptor Subtypes</th>
<th>Human Receptor Subtypes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radioligand Binding</td>
<td>[³⁵S]GTPγS Binding</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>NOP receptor</td>
<td>1.0 ± 0.5 (n = 5)</td>
<td>0.9 ± 0.2 (n = 7)</td>
</tr>
<tr>
<td>MOP receptor</td>
<td>2.4 ± 1.2 (n = 4)</td>
<td>0.7 ± 0.3 (n = 7)</td>
</tr>
<tr>
<td>KOP receptor</td>
<td>64.0 ± 11.0 (n = 2)</td>
<td>2.6 ± 1.4 (n = 7)</td>
</tr>
<tr>
<td>DOP receptor</td>
<td>N.D.</td>
<td>18.0 ± 20.0 (n = 11)</td>
</tr>
</tbody>
</table>

N.D., not done.

ᵃAgonistic potencies (EC₅₀ [nM]) of the reference compounds nociceptin (NOP receptor), DAMGO (MOP receptor), U-69, 593 (KOP receptor) and SNC 80 (DOP receptor), were 2.3 ± 0.9 (n = 5), 90.0 ± 38.0 (n = 5), 22.0 ± 6.0 (n = 6), and 4.7 ± 2.1 (n = 4), respectively.ᵇEfficacy of 100% is defined as maximum [³⁵S]GTPγS binding induced by stimulation with the reference compounds.
# TABLE 2

**ED$_{50}$-values and 95% CIs for cebranopadol and morphine in animal models of acute and chronic pain.**

<table>
<thead>
<tr>
<th>Pain Model</th>
<th>Route</th>
<th>Cebranopadol [µg/kg] (95% CI)</th>
<th>Morphine [mg/kg]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tail-flick, rat i.v.</td>
<td></td>
<td>5.6 (4.4–7.0)</td>
<td>1.1$^a$</td>
</tr>
<tr>
<td>Tail-flick, rat p.o.</td>
<td></td>
<td>25.1 (20.7–30.4)</td>
<td>55.7$^a$</td>
</tr>
<tr>
<td>Tail-flick, rat s.c.</td>
<td></td>
<td>N.D.</td>
<td>1.6 (1.3–2.1)</td>
</tr>
<tr>
<td>CFA-induced arthritic pain, rat i.v.</td>
<td></td>
<td>5.5 (3.2–21.0)</td>
<td>1.0$^b$</td>
</tr>
<tr>
<td>Bone cancer pain, rat i.v.</td>
<td></td>
<td>3.6 (1.6–7.0)</td>
<td>1.3 (0.8–1.9)</td>
</tr>
<tr>
<td>SNL-induced neuropathy, rat i.v.</td>
<td></td>
<td>0.8 (0.5–1.1)</td>
<td>3.7$^c$</td>
</tr>
<tr>
<td>STZ-induced neuropathy, rat i.v.</td>
<td></td>
<td>0.5 (0.2–0.8)</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

N.D., not done.

$^a$Tzschentke et al., 2006; $^b$Schiene et al., 2011; $^c$Christoph et al., 2007
TABLE 3
Summary (mean ± SD) of calculated basic pharmacokinetic parameters of cebranopadol after single intravenous administration to male Sprague-Dawley rats (n = 4).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>160 µg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C₀ ng/mL</td>
<td>22.8 ± 1.01</td>
</tr>
<tr>
<td>AUC h·ng/mL</td>
<td>22.2 ± 3.73</td>
</tr>
<tr>
<td>t₁/₂,z h</td>
<td>4.52 ± 0.82</td>
</tr>
<tr>
<td>CL L/kg/h</td>
<td>7.37 ± 1.38</td>
</tr>
<tr>
<td>Vz L/kg</td>
<td>47.1 ± 5.34</td>
</tr>
</tbody>
</table>

C₀, extrapolated concentration at the time of intravenous bolus administration (t = 0 h); AUC, area under the plasma concentration-time curve extrapolated to infinity; t₁/₂,z, terminal half-life; CL, total clearance; Vz, apparent volume of distribution during the terminal phase of disposition.
Fig. 2
Fig. 3
Cebranopadol dose [μg/kg i.v.]

Ipsilateral:
- ▼ Vehicle
- ■ 2.4
- ● 8.0
- ◆ 24.0

Contralateral:
- ▲ Vehicle
- □ 2.4
- ○ 8.0
- ◈ 24.0

% of maximum possible effect vs Time after administration [min]

Fig. 4
Cebranopadol dose [µg/kg i.v.]

*Diabetic:*
- Vehicle
- 0.24
- 0.8
- 2.4

*Non-diabetic:*
- Vehicle
- 0.24
- 0.8
- 2.4

Fig. 5
Fig. 6
Fig. 7
Fig. 8